Terms: = Liver cancer AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978
13 results:
1. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
2. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
3. Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions.
Singh I; Singh A
Curr Oncol Rep; 2023 Jun; 25(6):539-547. PubMed ID: 36928826
[TBL] [Abstract] [Full Text] [Related]
4. Clinical findings in 39 individuals with Bohring-Opitz syndrome from a global patient-driven registry with implications for tumor surveillance and recurrence risk.
Russell BE; Kianmahd RR; Munster C; Yu A; Ahad L; Tan WH
Am J Med Genet A; 2023 Apr; 191(4):1050-1058. PubMed ID: 36751885
[TBL] [Abstract] [Full Text] [Related]
5. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
6. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract] [Full Text] [Related]
7. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract] [Full Text] [Related]
8. RUNX1 mutations promote leukemogenesis of myeloid malignancies in asxl1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract] [Full Text] [Related]
9. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
10. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract] [Full Text] [Related]
11. Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
Man N; Tan Y; Sun XJ; Liu F; Cheng G; Greenblatt SM; Martinez C; Karl DL; Ando K; Sun M; Hou D; Chen B; Xu M; Yang FC; Chen Z; Chen S; Nimer SD; Wang L
Blood; 2017 May; 129(20):2782-2792. PubMed ID: 28381396
[TBL] [Abstract] [Full Text] [Related]
12. asxl1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract] [Full Text] [Related]
13. Functional and cancer genomics of ASXL family members.
Katoh M
Br J Cancer; 2013 Jul; 109(2):299-306. PubMed ID: 23736028
[TBL] [Abstract] [Full Text] [Related]
